Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04208646 | Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis | PHASE2 | COMPLETED | 106 | — | — | May 16, 2020 | Jul 31, 2023 | Aug 1, 2023 | 7 | China |
The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points；96 points mean a worse outcome,will be tested at 24 weeks after the first injection
| Arm | Type | Description |
|---|---|---|
| Mesenchymal progenitor cells Dosage 1 | EXPERIMENTAL | Mesenchymal progenitor cells low-dose group |
| Mesenchymal progenitor cells Dosage 2 | EXPERIMENTAL | Mesenchymal progenitor cells high-dose group |
| No mesenchymal progenitor cells | PLACEBO_COMPARATOR | No mesenchymal progenitor cells |
| Name | Type | Description |
|---|---|---|
| Mesenchymal progenitor cells | BIOLOGICAL | Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use |
| No mesenchymal progenitor cells | BIOLOGICAL | No mesenchymal progenitor cells for intra- articular use |
Inclusion Criteria: 1. Subjects who understand and voluntarily sign the consent form before this study； 2. According to the diagnostic criteria (American Rheumatology Association, clinical + radiology criteria), patients with knee osteoarthritis are definitely diagnosed； 3. Age: 40-75, males and fe...